CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
Condition: Pain; Neoplasms; Chronic Pain
MeSH terms: Chronic Pain
Intervention: Cebranopadol; Morphine Prolonged Release
Intervention description: Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.; Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
Intervention MeSH terms: Morphine
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 200.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: cancer pain; neuropathic related cancer pain; morphine; cebranopadol (GRT6005); Numerical Rating Scale

Summary:

      Pain is one of the most common symptoms associated with malignant tumor. The purpose of this
      trial is to determine whether cebranopadol is as effective in patients with cancer related
      pain as morphine sulfate prolonged release (PR).
    

Eligibility criteria:

        Inclusion Criteria:

          1. Signed informed consent.

          2. Negative pregnancy test before first dose.

          3. Female and male participants willing to use acceptable and highly effective methods of
             birth control.

          4. The following criteria must be fulfilled by participants:

               1. Require daily analgesia for their pain,

               2. Diagnosed with active cancer,

               3. Receiving daily opioid treatment at doses not higher than 90 mg oral morphine or
                  its equivalent (World Health Organization Step II and Step III analgesics) for an
                  appropriate length of time,

               4. Participants must be dissatisfied with their current pain treatment,

               5. Participants must be suffering from cancer-related but not cancer therapy-related
                  chronic pain for a period of 4 weeks or more prior to enrollment.

          5. Eastern Cooperation Oncology Group (ECOG) score 2 or below.

          6. Average pain intensity over the last 24 hours of 5 or more calculated from the pain
             assessments recorded during the last 3 days prior to randomization.

          7. Compliance with the use of the electronic diary defined as at least 3 out of 4 of the
             24 hour Numerical Rating Scale entries available during the last 4 days prior to and
             including the day of allocation to treatment.

        Exclusion Criteria:

          1. Evidence of ongoing alcohol and or drug abuse and/or a history of alcohol and/or drug
             abuse within the last 2 years.

          2. A clinically significant disease other than cancer which in the investigator's opinion
             may affect efficacy or safety assessments e.g., significant unstable cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious disease,
             psychiatric (resulting in disorientation, memory impairment or inability to report
             accurately) or metabolic disorders.

          3. Any gastrointestinal disorder that could affect the absorption and/or elimination of
             Investigational Medicinal Product.

          4. Any planned major surgery during the trial.

          5. Known to or suspected of not being able to comply with the trial protocol and the use
             of Investigational Medicinal Product.

          6. History of seizure disorder and/or epilepsy or any condition associated with a
             significant risk of seizure or epilepsy.

          7. Known history and/or presence of cerebral tumor or cerebral metastases.

          8. Moderate to severe hepatic impairment corresponding to Child-Pugh classification B and
             C. Impaired hepatic cellular integrity indicated by aspartate transaminase or alanine
             transaminase greater than 3 times the upper limit of normal at the Enrollment Visit.

          9. Inadequate baseline bone marrow reserve with a white blood cell count below 2000/µL, a
             platelet count 100 000/µL or less, and a hemoglobin level below 8 g/dL at the
             Enrollment Visit.

         10. Impaired renal function. Creatinine clearance less than 60 mL per minute(as per
             amendment 45 mL per minute) at the Enrollment Visit (calculated from the
             Cockcroft-Gault formula).

         11. Forbidden concomitant medications

         12. Uncontrolled hypertension

         13. Clinically relevant history of hypersensitivity, allergy or contraindications to
             opioid medication or any of the excipients of morphine sulfate (Prolonged Released or
             Immediate Release), or cebranopadol film-coated tablets.

         14. Chronic hepatitis B or C, or human immunodeficiency virus (HIV) known by history, or
             presence of active hepatitis B or C within the 3 months before the Enrollment Visit.

         15. History of torsade de pointes and/or presence of risk factors for torsade de pointes
             (e.g., heart failure, hypokalemia, or bradycardia).

         16. Marked prolongation of corrected QT interval (Fridericia) (greater than 450
             milliseconds) at the Enrollment Visit.

         17. Employees of the sponsor, investigator, or trial site or family members of the
             employees, sponsor, or investigator.

         18. Concurrent participation in another trial or planning to be enrolled in another
             clinical trial (i.e., administration of experimental treatment in another clinical
             trial) during the course of this trial.

         19. Previous participation in this or other trials with cebranopadol with the following
             exceptions:

               -  Participants who failed enrollment in this trial only because of exclusion
                  criterion 10, and who may now be eligible can be re-enrolled.

               -  Participants who failed enrollment due to technical failure of equipment (e.g.,
                  ECG machine and e-diary device).

         20. Participant has received an experimental drug or used an experimental medical device
             within 30 days before the planned start of treatment.

         21. Currently not receiving opioid treatment for cancer-related pain at the enrollment
             visit (i.e., opioid naïve).